The antibody–drug conjugate landscape 💥A great mini-review of ADC development, showcasing advancements in targets, drugs, antibodies, linkers, and conjugation methods👇 nature.com/articles/d4157…

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and TNBC: TROPION-PanTumor01 Study 🔍85 pts, heavily pretreated HR+/HER2- and TNBC ORR➡️27% and 32% PFS➡️8.3 and 4.8 mo OS➡️ NR and 13.5 mo ILD➡️1 pts No treatment-related deaths OncoAlert ascopubs.org/doi/10.1200/JC…

The safety of T-DXd with a focus on ILD and/or pneumonitis: meta‐analysis 🔍13 study, 1428 pts >G3 TEAEs➡️52.6% (G5: 5.4%) Discontinuation➡️14.4% >G3 ILD➡️2.2% (G5: 0.5%) 6.4 mg/kg ILD (all)➡️14.9% >G3 ILD➡️3.1% 5.4 mg/kg ILD (all)➡️8.0% >G3 ILD➡️0.4% OncoAlert

The latest version of AlphaFold models how proteins interact with other molecules — but DeepMind restricts access to the tool go.nature.com/4dsMcYP

I’m excited to share the story of building CrossBridge Bio with Kyoji Tsuchikama at #ASPET2024! Great science + A Great Team = High Probability of Success!

Funding secured…for our lead program. Official PR coming soon, but I had to share. Top score to boot! Thankful for the team I’ve been able to assemble! Go, @crossbridgebio! Thanks, CPRIT, for your support!

Why was IMpassion132 negative? And what’s the path forward for improving outcomes in early recurrent TNBC? Great discussion by Sara Tolaney (Sara Tolaney), recapitulating the current status & future hopes for one of the most challenging presentations of breast cancer. #ESMOBreast24

Detailed safety data on TB01 presented by Komal Jhaveri, MD, FACP, FASCO. Key tox with Dato-DXd: stomatitis (55%), mostly G1-2 with early onset and ocular toxicities (40%), mostly G1, median onset 65d. ILD is rare (3.3%) but potentially severe. Most common tox in the chemo arm were hematologic.

Giuseppe Curigliano (G Curigliano MD PhD) highlights key activity and toxicity data with the three most advanced Trop2-ADCs in the clinic for breast cancer. #ESMOBreast24 #ESMOAmbassadors ESMO - Eur. Oncology

Pr Egbert Smit elegantly suggests that TROP-2 ADCs with a topo-1 inhibitor payload (deruxtecan, govitecan…) are not better that old fashioned topo-1 inhibitors such as irinotecan or topotecan.

T-DXd in Advanced Solid Tumors With Human HER2 Amplification Identified by Plasma cfDNA Testing 🔍Previously received a median of 3 lines of treatment, 62 patients, 13 cancer types ORR➡️56.5% OncoAlert ascopubs.org/doi/10.1200/JC…

ADC stability ≠ ADC tolerability In medio stat virtus

Excited to announce the close of our $10M seed financing! We’ve got a good group of investors aligned with supporting the derisking of our next-generation ADC platform! businesswire.com/news/home/2024…

Cancer cells often become unresponsive to multiple types of therapy. It emerges that these ‘cross-resistant’ tumour cells release lipids that reprogram monocytes to stop them from activating tumour-targeting T cells go.nature.com/3BdF0BJ

Looking for weekend reading material? Check out this Review by Anthony Letai MD PhD and Hugues de The on the critical role of conventional chemotherapy in cancer treatment and the knowledge gaps that persist. Dana-Farber bit.ly/41Hq89j

📃Don't miss this Comment Nature Cancer 's Focus Issue - 2024 in Review: 'Toward clinical applications of #spatialomics in #cancerresearch' ✏️By Cameron Walker & Michael Angelo 🔗doi.org/10.1038/s43018…

NCI-supported researchers Memorial Sloan Kettering Cancer Center found that immune triads, which are clusters of three different types of immune cells, in tumors are required for effective #immunotherapy in preclinical models. Find out more in this press release. go.nih.gov/sQKfuiJ

Tomatoes lose their bitterness and toxicity as they ripen thanks to DNA demethylation, the hormone ethylene, and key transcription factors, finds a new Science Advances study. scim.ag/3EOMHQ4

Trastuzumab deruxtecan (T-DXd) doesn’t just target HER2! 🔘Even HER2-low & HER2-neg tumors respond! 🔘Extracellular proteases activate the payload. 🔘A whisper to the immune system: Attack. Nature Communications OncoAlert nature.com/articles/s4146…

This slide really didn't last long at all... ORM-5029 has now been discontinued. 2/3 degrader antibody conjugates (DACs) removed from clinical development this month! #AACR25 #ADC